Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
Authors: Salim Yusuf, Hans‐Christoph Diener, Ralph L. Sacco, Otto W. Witte, Stephanie Ôunpuu, William A Lawton, Yuko Palesch, Renée H. Martin, Gregory W. Albers, Philip M. Bath, Natan M. Bornstein, Bernard P.L. Chan, Christopher Chen, Luı́s Cunha, Björn Dahlöf, Jacques De Keyser, Geoffrey A. Donnan, Conrado J. Estol, Philip B. Gorelick, Vivian Gu, Karin Hermansson, Lutz Hilbrich, Markku Kaste, Chuanzhen Lü, Thomas Machnig, Prem Pais, Robin Roberts, Veronika Skvortsova, Philip Teal, Danilo Toni, Cam P. VanderMaelen, Thor Voigt, Michael A. Weber, Byung‐Woo Yoon
DOI: https://doi.org/10.1056/nejmoa0804593
Publish Year: 2008
